Quality | 2017.08.15
Asymmetrex’s New Patent Issued for Counting and Evaluating Therapeutic Adult Tissue Stem Cells Also Supports Company’s New Stem Cell Production Services
Since the beginnings for stem cell research and stem cell medicine, it has not been possible to count tissue stem cells, determine their therapeutic dose, certify their quality, or evaluate the effects of drugs and environmental agents on their function. But, today the US Patent & Trademark Office signals the end of this situation by its scheduled issue, to Massachusetts biotechnology start-up company Asymmetrex, the first patent for specific quantification of adult tissue stem cells and certification of agents that affect their function.
(PRWeb August 15, 2017)
Read the full story at http://www.prweb.com/releases/2017/08/prweb14601164.htm
For more information, please visit
http://www.prweb.com/releases/2017/08/prweb14601164.htm
